Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy.
Midori ShimaNobuaki SuzukiHidekazu NishikiiKagehiro AmanoYoshiyuki OgawaRyota KobayashiRyoto OzakiKoichiro YoneyamaNarumi MizunoEmiko SakaidaMakoto SaitoTakashi OkamuraToshihiro ItoNorimichi HattoriSatoshi HigasaYoshinobu SekiKeiji NogamiPublished in: Thrombosis and haemostasis (2024)
These results suggest that emicizumab prophylaxis has a favorable benefit-risk profile in PwAHA regardless of eligibility for IST.
Keyphrases